Cargando…

A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

Detalles Bibliográficos
Autor principal:	Cakir, Banu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790345/ https://www.ncbi.nlm.nih.gov/pubmed/33415491 http://dx.doi.org/10.1007/s10096-020-04112-2

Ejemplares similares

A novel approach to managing COVID-19 patients: results of lopinavir plus doxycycline cohort—authors’ reply
por: Cag, Yasemin, et al.
Publicado: (2021)

A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort
por: Cag, Yasemin, et al.
Publicado: (2020)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study
por: Lora-Tamayo, Jaime, et al.
Publicado: (2021)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
por: Cattaneo, Dario, et al.
Publicado: (2020)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

Lopinavir-Ritonavir Associated Acute Kidney Injury Is Not Related to Crystalluria in Critically Ill COVID-19 Patients
por: Arrestier, Romain, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Doxycycline as an Alternative to Azithromycin in Elderly Patients
por: Malek, Alexandre Elias, et al.
Publicado: (2021)

Reply to the letter to the Editor “Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts”
por: Simon, Nicolas, et al.
Publicado: (2020)

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b
por: Hong, Sun In, et al.
Publicado: (2020)

Empirical treatment with doxycycline of fever of intermediate duration
por: Guirao-Arrabal, Emilio, et al.
Publicado: (2021)

Is the efficacy of remdesivir so different from that of lopinavir–ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review
por: Duarte, Tiago Isidoro, et al.
Publicado: (2021)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
por: Hakim, James G, et al.
Publicado: (2018)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir()
por: Gimeno Castillo, Javier, et al.
Publicado: (2021)

Doxycycline for haematopoietic stem cell transplantation-related thrombotic microangiopathy
por: Izzedine, Hassane, et al.
Publicado: (2010)

Malaria Prophylaxis Failure with Doxycycline, Central African Republic, 2014
por: Madamet, Marylin, et al.
Publicado: (2015)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
por: Binois, Yannick, et al.
Publicado: (2020)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
por: Purwati,, et al.
Publicado: (2021)

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
por: Wechalekar, A D, et al.
Publicado: (2017)

Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19
por: Marzolini, Catia, et al.
Publicado: (2020)

Pro-apoptotic effect of doxycycline and hydroxychloroquine on B-cell lymphoma induced by C. burnetii
por: Melenotte, Cléa, et al.
Publicado: (2017)

Acute dystonic reaction due to a combination of chloroquine and doxycycline in an emergency psychiatry setting
por: Nachane, Hrishikesh B., et al.
Publicado: (2020)

Idiopathic erythema annulare centrifugum successfully treated with doxycycline: A viable therapeutic option?
por: Fidanzi, Cristian, et al.
Publicado: (2023)

Doxycycline and eradication of microfilaremia in patients with loiasis.
por: Brouqui, P, et al.
Publicado: (2001)

Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 for patients with dementia
por: Liu, Ting-Hui, et al.
Publicado: (2023)

Long-term doxycycline and lung function in chronic obstructive pulmonary disease: A pilot observation
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2014)

Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2
por: Francini, Edoardo, et al.
Publicado: (2020)

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
por: Karolyi, Mario, et al.
Publicado: (2020)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

A quick glance at publications on COVID-19 and ophthalmology
por: Banu, Sabera, et al.
Publicado: (2020)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rrk7irl3ti53af76orb5dqfhtf